All Oncology News

Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.

Pirtobrutinib yields superior overall response rates and promising progression-free survival compared with ibrutinib in chronic lymphocytic leukemia.

Adding epcoritamab to lenalidomide and rituximab improved PFS and ORR vs the combination alone in patients with relapsed/refractory follicular lymphoma.

Gintemetostat demonstrates efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

Epcoritamab plus R-mini-CHOP delivered deep responses with manageable safety in elderly, high-risk patients with newly diagnosed DLBCL.

ctDNA at end of treatment strongly predicted outcomes across lymphoma subtypes, outperforming imaging and supporting its role in personalized disease monitoring.

The AGAVE-201 trial showed successful transition from axatilimab 0.3 mg/kg biweekly to 0.6 mg/kg monthly in cGVHD.

Early phase 3 data showed signals of efficacy with the addition of odronextamab to CHOP in patients with previously untreated DLBCL and high-risk features.

Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile.

KRd improved PFS, deepened responses, and led to higher MRD negativity vs VRd in newly diagnosed multiple myeloma.

In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.

Elranatamab plus iberdomide showed a 95.5% response rate in patients with BCMA-naive relapsed/refractory myeloma per early MagnetisMM-30 data.

Future AML study analyses may focus on measurable residual disease to predict OS through non-intensive modern treatment backbones.

Findings from a retrospective analysis identified Black race as an independent predictor of inferior survival outcomes with intensive chemotherapy in AML.

Lisaftoclax demonstrated efficacy and safety for the treatment of patients with relapsed/refractory CLL/SLL.

In the CaDAnCe-101 study, BGB-16673 was tolerable, effective, and showed sustained disease control in high-risk, heavily pretreated, relapsed/refractory CLL/SLL.

Zanubrutinib plus R-CHOP produced a high ORR and CR rate in untreated DLBCL with certain gene expression.

Thirty percent of families of pediatric patients with ALL receiving chemotherapy experienced catastrophic financial toxicities.

Administering cilta-cel earlier in treatment improves clinical outcomes, with superior PFS and OS rates compared to later intervention.

Fixed-duration venetoclax combinations delivered PFS comparable with continuous ibrutinib in the phase 3 CLL17 trial.

The phase 2 EndRAD study found that removing TBI from conditioning did not compromise efficacy in pediatric or young adult patients with B-cell ALL.

Findings from an exploratory analysis of IMvigor011 support the use of serial ctDNA testing to guide atezolizumab use in MIBC.

Intravesical cretostimogene grenadenorepvec was efficacious and safe in high-risk BCG-naive non–muscle-invasive bladder cancer.

Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.

Gemcitabine intravesical system in BCG-unresponsive, high-risk NMIBC led to high CR rates and low radical cystectomy rates.

Rucaparib delivers consistent rPFS benefits across all age groups in BRCA-mutated mCRPC, reinforcing its role as an effective treatment option.

Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

Peripheral neuropathy was linked with improved efficacy outcomes after treatment with first-line enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

At 48 months, the majority of patients with VHL disease–associated tumors remained in response following treatment with belzutifan.

Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.